Rifaximin Ameliorates Non-alcoholic Steatohepatitis in Mice Through Regulating gut Microbiome-Related Bile Acids

• Main Authors: Jie Jian (Author), Mei-Tong Nie (Author), Baoyu Xiang (Author), Hui Qian (Author), Chuan Yin (Author), Xin Zhang (Author), Menghui Zhang (Author), Xuan Zhu (Author), Wei-Fen Xie (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Non-alcoholic steatohepatitis (NASH) is the progressive stage of non-alcoholic fatty liver disease (NAFLD). The non-absorbable antibiotic rifaximin has been used for treatment of irritable bowel syndrome, traveling diarrhea, and hepatic encephalopathy, but the efficacy of rifaximin in NASH patients...